Compare SELLAS Life Sciences Group Inc. Common Stock (SLS) vs Westinghouse Air Brake Technologies Corporation Common Stock (WAB) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
SELLAS Life Sciences Group Inc. Common Stock vs Westinghouse Air Brake Technologies Corporation Common Stock — how do they compare? SELLAS Life Sciences Group Inc. Common Stock trades at $11.75 (market cap $2.51B), while Westinghouse Air Brake Technologies Corporation Common Stock trades at $286.02 (market cap $48.39B). The key difference: Westinghouse Air Brake Technologies Corporation Common Stock is far larger — about 19.3× SELLAS Life Sciences Group Inc. Common Stock's market cap, and Westinghouse Air Brake Technologies Corporation Common Stock pays a 0.43% dividend while SELLAS Life Sciences Group Inc. Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold SELLAS Life Sciences Group Inc. Common Stock for 0 Days and Westinghouse Air Brake Technologies Corporation Common Stock for 0 Days on average.
| SLS | WAB | |
|---|---|---|
Market Cap | $2.51B | $48.39B |
Volume | 6,359,048 | 960,464 |
Sector | Health | Industrials |
52-Week High | $15.46 | $305.79 |
52-Week Low | $1.39 | $193.43 |
Typical Hold Time | 0 Days | 0 Days |
Enterprise Value | $2.37B | $54.30B |
Dividend Yield | — | 0.43% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
SELLAS Life Sciences (SLS) trades at $12.41, up 4.02% today, with a bullish technical signal from moving averages but mixed oscillators. The company reported no revenue in 2025, with a net loss of $26.86 million, negative ROE and ROA, and a high P/B ratio of 18.2. Recent news includes a law firm investigation into investor claims and positive preclinical data for SLS009 in pancreatic cancer models presented at the AACR conference.
The outlook hinges on upcoming clinical trial results, particularly the Phase 3 REGAL trial for GPS in AML, with topline data expected in Q4 2026. While analyst consensus is unanimously bullish, significant risks include the binary nature of trial outcomes, ongoing legal scrutiny, and persistent negative profitability metrics. The stock's recent surge of ~300% year-to-date reflects high investor optimism but also heightened volatility.
Wabtec (WAB) trades at $286.51, up 0.26% today, with a neutral technical signal. The company shows strong fundamentals, with Q2 2026 EPS of $2.76 beating estimates and revenue growth to $12.0B projected for 2026. A $700M+ African rail services deal and raised full-year guidance highlight positive business momentum. Key support rests at $284, with resistance at $288.
The outlook is positive, driven by earnings beats, margin expansion, and a robust backlog. Risks include premium valuation (P/E 38.56) and investing cash outflows. Analyst consensus is bullish with a $326.50 price target, suggesting ~14% upside from current levels.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About SELLAS Life Sciences Group Inc. Common Stock
SELLAS Life Sciences is a late-stage clinical biopharmaceutical company developing therapies for cancer. Its programs include a WT1-targeting cancer immunotherapy and a selective CDK9 inhibitor.
Read more on SLS →About Westinghouse Air Brake Technologies Corporation Common Stock
Westinghouse Air Brake Technologies Corporation, known as Wabtec, provides equipment, systems, and services for the freight rail and passenger transit industries. Its Freight segment supplies locomotives, braking systems, and signaling technology, while its Transit segment supports passenger rail systems worldwide.
Read more on WAB →
